Australian researchers spearhead paradigm shift in melanoma treatment

Australian researchers spearhead paradigm shift in melanoma treatment

20 September 2021

In what has been described as a paradigm shift in the treatment of melanoma, drug therapy looks set to become the standard treatment for high-risk early stage melanoma patients to stop disease spread and save lives.

Promising results from an international multi-centre clinical trial, which included researchers and patients from Melanoma Institute Australia (MIA), were presented this weekend at the prestigious European Society for Medical Oncology (ESMO) Congress.

Results showed giving high-risk Stage II melanoma patients the same immunotherapy drugs approved for use in advanced melanoma patients, reduced the risk of their disease returning or death by 35%.

Study author Professor Georgina Long AO, Co-Medical Director of Melanoma Institute Australia and of The University of Sydney, said the findings would result in a paradigm shift in treatment of early stage patients.

‘We are using drug therapy already proven to be life-saving for advanced melanoma patients, to stop the disease in its tracks in earlier stage patients,’ Professor Long said. ‘These exciting clinical trial results are strong evidence to support approval for this immunotherapy to become standard treatment for high-risk  Stage II patients in Australia.’

The clinical trial demonstrated that giving pembrolizumab (Keytruda™) after surgery to patients with Stage IIB or IIC melanoma (deemed at high risk of spread due to tumour thickness or ulceration) reduced the risk of the disease returning or death by 35% compared to placebo. At 12 months, only 9.5% of patients on pembrolizumab had their melanoma progress, compared to 16.9% in the placebo group.

In the last decade, the approval of immunotherapy for Stage III and IV melanoma patients has dramatically increased survival rates, with more than 50% of these patients now essentially cured.

However, there are no immunotherapy drugs currently approved for use in Stage II melanoma patients. They instead have to adopt a ‘watch-and-wait’ approach after surgery to see if their cancer will return or spread. Patients with thick Stage II melanoma also often undergo an invasive Sentinel Node Biopsy to check for disease spread, with drug therapy only available once their disease has spread to their lymph nodes (Stage III).

Fellow study author Professor Richard Scolyer AO, Co-Medical Director of Melanoma Institute Australia and of The University of Sydney, says the clinical trial results stand to transform how earlier stage disease is managed.

‘By giving this immunotherapy treatment at an earlier stage, we are proactively preventing melanoma spread,’ Professor Scolyer said.

Australia has the highest melanoma rates in the world with one person diagnosed with the disease every 30 minutes. An estimated 1300 Australians are expected to die from melanoma this year.

Following these clinical trial results, it is hoped pembrolizumab will soon come before the Pharmaceutical Benefits Advisory Committee (PBAC) for approval for use in these patients in Australia.

‘This proactive approach to preventing disease spread represents a significant step forward in our mission of reaching zero deaths from melanoma,’ Professor Scolyer added.

___________________________________________________________________________

The full data set was presented at ESMO on Saturday 18 September 2021 at 11:05pm (AEST) by Associate Professor Jason Luke in a presentation entitled: “Pembrolizumab versus placebo after complete resection of high-risk stage II melanoma: Efficacy and safety results from the Keynote 716 double-blinded phase III trial”.
Melanoma Institute Australia is affiliated with The University of Sydney and Professor Scolyer and Professor Long lead the Translational Research Group at the Charles Perkins Centre.
 

Media contact:

Jennifer Durante |media@melanoma.org.au | 0412 798 990

Arden Anglican School wins SunSafe Ambassador competition
13 Dec 2018

Arden Anglican School wins SunSafe Ambassador competition

Three students from Arden Anglican School in Epping have won Melanoma Institute Australia’s (MIA) inaugural SunSafe Student Ambassador Award.

DON'T CLOUD THE SUN-SAFE MESSAGE
08 Dec 2018

DON'T CLOUD THE SUN-SAFE MESSAGE

Mark Whittaker’s ‘Here comes the sun; Defending our summer rays’ (GW 24 Nov) clouds the sun-safe message – which could have disastrous consequences.

Professor Georgina Long named as one of world's most highly cited researchers
04 Dec 2018

Professor Georgina Long named as one of world's most highly cited researchers

Professor Georgina Long is among only 12 researchers from the University of Sydney to be named in the 2018 Highly Cited Researchers List.

Aussies need to protect themselves from 'everyday' sun damage
01 Dec 2018

Aussies need to protect themselves from 'everyday' sun damage

‘Wearing sunscreen should be as automatic as wearing a seatbelt. Both are potential life savers.

The Poche Centre to host 3D total-body imaging system as part of world-first initiative to save lives from melanoma
29 Nov 2018

The Poche Centre to host 3D total-body imaging system as part of world-first initiative to save lives from melanoma

A prestigious $10 million Australian Cancer Research Foundation grant has been awarded to ACEMID, an initiative that aims to use 3D total-body imaging and a remote medicine network to improve the detection and diagnosis of early-stage melanoma.

Major award for world-leaders in melanoma research
09 Nov 2018

Major award for world-leaders in melanoma research

Professor Georgina Long and Professor Richard Scolyer have been recognised as world leaders in melanoma research for their ground-breaking work that has changed the diagnosis and treatment landscape of melanoma world-wide, and tripled the life-expectancy of advanced melanoma patients. 

Melanoma Institute Australia shines at prestigious Cancer Research Awards
03 Nov 2018

Melanoma Institute Australia shines at prestigious Cancer Research Awards

Leading researchers from Melanoma Institute Australia have taken out the top accolades at the NSW Premier’s Awards for Outstanding Cancer Research.

Women of MIA lead the way in melanoma research at SMR
31 Oct 2018

Women of MIA lead the way in melanoma research at SMR

An impressive contingent of female delegates from Melanoma Institute Australia have presented findings across the whole spectrum of melanoma research at the Society for Melanoma Research 2018 Congress in Manchester, England.

Women of MIA lead the way in melanoma research at SMR
31 Oct 2018

Women of MIA lead the way in melanoma research at SMR - Copy

An impressive contingent of female delegates from Melanoma Institute Australia have presented findings across the whole spectrum of melanoma research at the Society for Melanoma Research 2018 Congress in Manchester, England.

Women of MIA lead the way in melanoma research at SMR
31 Oct 2018

Women of MIA lead the way in melanoma research at SMR - Copy

An impressive contingent of female delegates from Melanoma Institute Australia have presented findings across the whole spectrum of melanoma research at the Society for Melanoma Research 2018 Congress in Manchester, England.

Immune cell research presented at SMR
30 Oct 2018

Immune cell research presented at SMR

Over 800 researchers and clinicians from around the world were welcomed to Manchester for the 15th International Congress of the Society for Melanoma Research (SMR). Melanoma Institute Australia (MIA) has again sent an impressive number of delegates to present both oral presentations and posters with the latest in translational research.

Professor Georgina Long makes history as the first woman and first Australian to lead the Society for Melanoma Research
26 Oct 2018

Professor Georgina Long makes history as the first woman and first Australian to lead the Society for Melanoma Research

Professor Georgina Long makes history as the first woman and first Australian to lead the world’s most prestigious international melanoma research association.

Patients to benefit from updated skin tumour publications
26 Oct 2018

Patients to benefit from updated skin tumour publications

Two publications co-edited by MIA Co-Medical Director Professor Richard Scolyer are now available to healthcare professionals. They aim to provide assistance in the care and management of patients with skin cancer, including melanoma.

SunSafe Student Ambassador Program
25 Oct 2018

SunSafe Student Ambassador Program

Melanoma Institute Australia has introduced a new educational program to teach teenagers about the dangers of melanoma and the importance of sun safety. 

International collaboration the key to increasing survival
24 Oct 2018

International collaboration the key to increasing survival

"International collaboration remains the key to ensuring this pioneering research continues so we can increase survival rates for advanced melanoma patients and move us closer to achieving our goal of zero deaths from melanoma," says Professor Georgina Long, of the clinical trial results presented at ESMO 2018.

High-risk Stage III melanoma patients to benefit from Australia/Netherlands collaboration
23 Oct 2018

High-risk Stage III melanoma patients to benefit from Australia/Netherlands collaboration

Research that could change clinical practice for high-risk Stage III melanoma patients has been presented at the European Society for Medical Oncology (ESMO) Congress in Munich.

Monthly dose of immunotherapy allows flexibility for patients undergoing treatment
11 Oct 2018

Monthly dose of immunotherapy allows flexibility for patients undergoing treatment

A larger, monthly dose of immunotherapy can give melanoma patients more freedom without sacrificing effectiveness.

Australia's best minds in melanoma research converge on Melbourne
08 Oct 2018

Australia's best minds in melanoma research converge on Melbourne

The Australasian Melanoma Conference, hosted by the Australasian Melanoma Conference Committee, was held in Melbourne on the weekend, with many of MIA's clinicians in attendance.

Nobel Prize for novel cancer therapies
04 Oct 2018

Nobel Prize for novel cancer therapies

The two men who discovered checkpoint inhibitors, the brakes of the immune system, were awarded the Nobel Prize in Physiology or Medicine on Monday, October 1.

World Health Organisation launches 4th edition of Classification of Skin Tumours
31 Aug 2018

World Health Organisation launches 4th edition of Classification of Skin Tumours

The World Health Organisation (WHO) is releasing the 4th edition of Classification of Skin Tumours.